Scancell wins FDA fast-track status for melanoma immunotherapy

The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has secured a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, iSCIB1+, in advanced melanoma.